Security Snapshot

Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO) Institutional Ownership

CUSIP: 71880W501

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

24

Shares (Excl. Options)

647.13KFull value: 647,127 · shares · 30 Jun 2026

Price

$1.02

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, $0.0001 par value per share
Symbol
PHIO on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
647,127
Latest holder snapshot 5 signals
Total 13F value
$662,564
Portfolio coverage rank
0%
Share change
-21,363
Value change
-$33,984
Number of holders
24
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
12,067,869
SEC-reported price per share
$0.93
Insider filing price
$0.93
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • PHIO - Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share is tracked under CUSIP 71880W501.
  • 24 institutions reported positions in Q2 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 24 to 24 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $814.95KFull value: $814,950 · USD · 31 Mar 2026
    to
    $662.56KFull value: $662,564 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 24 institutions filings for Q2 2026.

Open SEC evidence

Security key

71880W501

13F reference period

Q2 2026

13F holders

24

13D/G owners

3

CIK / CUSIP context first

Open Q2 2026 holders PHIO full holder history Phio Pharmaceuticals Corp. SEC filings Phio Pharmaceuticals Corp. company facts Phio Pharmaceuticals Corp. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
PHIO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CVI Investments, Inc. 9.9% 0% $1,409,768 +$544,422 1,194,719 +63% CVI Investments, Inc. 31 Dec 2025
INTRACOASTAL CAPITAL, LLC 9.1% +30% $1,348,216 +$840,816 1,142,556 +166% Mitchell P. Kopin 31 Dec 2025
Orca Capital AG 4.9% -23% $770,351 -$231,251 538,707 -23% Orca Capital AG 08 Dec 2025
As of 30 Jun 2026, 24 institutional investors reported holding
647.13KFull value: 647,127 · shares · 30 Jun 2026
shares of Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO). This represents 5.4% of the company’s total
12.07MFull value: 12,067,869 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
9
Headline period
Q2 2026
Rows shown
1-9 of 9
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 12,510 $12,861 +$11,455 $1.03 4
2026 Q2 647,127 $662,564 -$33,984 $1.02 24
2026 Q1 668,490 $814,950 +$346,788 $1.22 24
2025 Q4 363,848 $382,314 +$184,258 $1.05 17
2025 Q3 188,486 $467,442 +$59,965 $2.48 11
2025 Q2 164,722 $387,355 +$164,978 $2.35 11
2025 Q1 100,618 $130,801 -$133,237 $1.30 10
2024 Q4 153,843 $277,072 +$183,357 $1.80 10
2024 Q3 28,506 $98,345 +$98,345 $3.45 6
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .